- Home
- NAII vs VYNE Comparison
NAII vs VYNE Comparison
Compare NAII & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAII
- VYNE
- Stock Information
- Founded
- NAII 1980
- VYNE 2003
- Country
- NAII United States
- VYNE United States
- Employees
- NAII 303
- VYNE N/A
- Industry
- NAII Medicinal Chemicals and Botanical Products
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- NAII Health Care
- VYNE Health Care
- Exchange
- NAII Nasdaq
- VYNE Nasdaq
- Market Cap
- NAII 28.0M
- VYNE 38.2M
- IPO Year
- NAII 1987
- VYNE 2018
- Fundamental
- Price
- NAII $4.70
- VYNE $2.19
- Analyst Decision
- NAII
- VYNE Strong Buy
- Analyst Count
- NAII 0
- VYNE 1
- Target Price
- NAII N/A
- VYNE $5.75
- AVG Volume (30 Days)
- NAII 17.6K
- VYNE 46.3K
- Earning Date
- NAII 11-07-2024
- VYNE 11-11-2024
- Dividend Yield
- NAII N/A
- VYNE N/A
- EPS Growth
- NAII N/A
- VYNE N/A
- EPS
- NAII N/A
- VYNE N/A
- Revenue
- NAII $113,796,000.00
- VYNE $486,000.00
- Revenue This Year
- NAII N/A
- VYNE $32.31
- Revenue Next Year
- NAII N/A
- VYNE N/A
- P/E Ratio
- NAII N/A
- VYNE N/A
- Revenue Growth
- NAII N/A
- VYNE 19.41
- 52 Week Low
- NAII $4.13
- VYNE $1.57
- 52 Week High
- NAII $7.37
- VYNE $4.48
- Technical
- Relative Strength Index (RSI)
- NAII 39.07
- VYNE 67.35
- Support Level
- NAII $4.22
- VYNE $1.79
- Resistance Level
- NAII $4.92
- VYNE $2.05
- Average True Range (ATR)
- NAII 0.39
- VYNE 0.15
- MACD
- NAII -0.05
- VYNE 0.03
- Stochastic Oscillator
- NAII 30.81
- VYNE 74.77
About NAII Natural Alternatives International Inc.
Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segment. The company derives the majority of revenue from Private-Label Contract Manufacturing which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.